National Institute on Aging; Notice of Closed Meetings, 26793-26794 [2013-10854]
Download as PDF
Federal Register / Vol. 78, No. 89 / Wednesday, May 8, 2013 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Place: National Institutes of Health, 1202,
6700B Rockledge Drive, Bethesda, MD 20817
(Telephone Conference Call).
Contact Person: Betty Poon, PHD,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
NIAID/NIH/DHHS, 6700B Rockledge Drive,
MSC 7616, Bethesda, MD 20892–7616, 301–
402–6891, poonb@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Clinical Trials Units for
NIAID Networks.
Date: June 5, 2013.
Time: 9:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 235,
6700A Rockledge Drive, Bethesda, MD 20817
(Telephone Conference Call).
Contact Person: Betty Poon, PHD,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
NIAID/NIH/DHHS, 6700B Rockledge Drive,
MSC 7616, Bethesda, MD 20892–7616, 301–
402–6891, poonb@mail.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Clinical Trials Units for
NIAID Networks.
Date: June 5, 2013.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 2C21/
23, 10401 Fernwood Building, Bethesda, MD
20892 (Telephone Conference Call).
Contact Person: Uday K. Shankar, PHD,
MSC, Scientific Review Officer, Scientific
Review Program, DEAS/NIAID/NIH/DHHS,
6700B Rockledge Drive, MSC 7616, Bethesda,
MD 20892–7616, 301–594–3193,
uday.shankar@nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Clinical Trails Unit for
NIAID Networks.
Date: June 6, 2013.
Time: 9:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 2C05,
10401 Fernwood Building, Bethesda, MD
20892 (Telephone Conference Call).
Contact Person: Robert C. Unfer, PHD,
Scientific Review Officer, Scientific Review
Program, DEA/NIAID/NIH/DHHS, 6700–B
Rockledge Dr., MSC–7616, Bethesda, MD
20892–7616, 301–496–2550,
robert.unfer@nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Clinical Trials Units for
NIAID Networks.
Date: June 12, 2013.
Time: 9:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Dated: May 2, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
VerDate Mar<15>2010
18:31 May 07, 2013
Jkt 229001
[FR Doc. 2013–10855 Filed 5–7–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Environmental
Health Sciences; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel; Conferences on
Environmental Health.
Date: June 4, 2013.
Time: 12:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Nat. Inst. of Environmental Health
Sciences, Keystone Building, 530 Davis
Drive, Research Triangle Park, NC 27709
(Telephone Conference Call).
Contact Person: Leroy Worth, Scientific
Review Officer, Scientific Review Branch,
Division of Extramural Research and
Training, Nat. Institute of Environmental
Health Sciences, P.O. Box 12233, MD EC–30/
Room 3171, Research Triangle Park, NC
27709, (919) 541–0670, worth@niehs.nih.gov.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel; Transition to Independence
(Careers) Development.
Date: June 6, 2013.
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
26793
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Garden Inn Durham
Southpoint Hotel, 7007 Fayetteville Road,
Durham, NC 27713.
Contact Person: Leroy Worth, Ph.D.,
Scientific Review Administrator, Scientific
Review Branch, Division of Extramural
Research and Training, Nat. Institute of
Environmental Health Sciences, P.O. Box
12233, MD EC–30/Room 3171, Research
Triangle Park, NC 27709, 919/541–0670,
worth@niehs.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation—Health Risks from
Environmental Exposures; 93.142, NIEHS
Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund
Hazardous Substances—Basic Research and
Education; 93.894, Resources and Manpower
Development in the Environmental Health
Sciences; 93.113, Biological Response to
Environmental Health Hazards; 93.114,
Applied Toxicological Research and Testing,
National Institutes of Health, HHS)
Dated: May 2, 2013.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–10870 Filed 5–7–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Asthma in
Older Adults.
Date: May 29, 2013.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, Suite 2C212, 7201
Wisconsin Avenue, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Jeanette Johnson, Ph.D.,
Scientific Review Branch, National Institute
E:\FR\FM\08MYN1.SGM
08MYN1
26794
Federal Register / Vol. 78, No. 89 / Wednesday, May 8, 2013 / Notices
on Aging, Gateway Building, 7201 Wisconsin
Avenue, Suite 2C212, Bethesda, MD 20892,
301–402–7705, JOHNSONJ9@NIA.NIH.GOV.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Mild
Cognitive Impairment.
Date: June 5, 2013.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, Suite 2C212, 7201
Wisconsin Avenue Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: William Cruce, Ph.D.,
Scientific Review Branch, National Institute
on Aging, Gateway Building, 7201 Wisconsin
Avenue, Suite 2C212, Bethesda, MD 20892,
301–402–7704, crucew@nia.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: May 1, 2013.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–10854 Filed 5–7–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Use of Oligodeoxynucleotide
as Neuroprotectants in Cerebral and
Other Ischemic Injury
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services, is
contemplating the grant of an exclusive
license to practice the inventions
embodied in U.S. provisional patent
application No. 60/176/115 (E–078–
2000/0–US–01) filed 1/14/2000; PCT
application No. PCT/US01/01122 (E–
078–2000/0–PCT–02) filed 1/12/2001;
U.S. patent No. 7,521,063 (E–078–2000/
1–US–01) filed 07/12/2002 and issued
04/21/2009; U.S. patent No. 7,919,477
(E–078–2000/1–US–02) filed 05/10/
2007and issued 04/05/2011; U.S. patent
No. 8,232,259 (E–078–2000/1–US–03)
filed 02/11/2011 and issued 07/31/2012;
E.U. patent No. 1322655 (E–078–2000/
0–EP–03) filed 1/12/2001 and issued 11/
14/2007 and validated in AT, GB, and
IE (E–078–2000/0–AT–05, E–078–2000/
0–GB–07, & E–078–2000/0–IE–08) and
issued 12/13/2007 as patent No.
6031430 and validated in Germany (E–
078–2000/0–DE–06); and E.U. patent
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
17:56 May 07, 2013
Jkt 229001
application No. 07021557.9 (E–078–
2000/0–EP–04) filed 11/05/2007; each
entitled ‘‘Oligodeoxynucleotide and Its
Use to Induce an Immune Response’’; by
Klinman et al. (FDA) to Oregon Health
Sciences University having a place of
business at 3181 SW. Sam Jackson Park
Rd. Portland, Oregon 97239. The patent
rights in this invention have been
assigned to the United States of
America.
DATES: Only written comments and/or
application for a license that are
received by the NIH Office of
Technology Transfer on or before June
7, 2013 will be considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Tedd Fenn, Office of Technology
Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Email:
fennea@mail.nih.gov; Telephone: 301–
435–5031; Facsimile: 301–402–0220.
SUPPLEMENTARY INFORMATION: The
prospective worldwide exclusive
license will be royalty bearing and will
comply with the terms and conditions
of 35 U.S.C. 209 and 37 CFR 404.7. The
prospective exclusive license may be
granted unless, within thirty (30) days
from the date of this published Notice,
NIH receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR 404.7.
The subject patents relate to
compositions and methods of use of
oligodeoxynucleotides (ODNs)
expressing CpG motifs to induce
immune responses. These ODNs mimic
signals of invading pathogens. ODN
motifs trigger immune system responses
via Toll-like receptor 9 (TLR9). They
also mediate inflammatory responses to
tissue injury, such as those responses
following ischemic damage to the
central nervous system. Structural
differences between various ODNs may
stimulate distinct cell populations,
allowing selective targeting of immune
responses for therapeutic purposes.
Non-human primate and animal models
using specific ODNs for
pharmacological preconditioning have
shown that ODNs may act
therapeutically as neuroprotectants from
ischemic damage. These TLR ligands as
may be useful therapeutically as
neuroprotectants in cerebral ischemic
injury.
The field of use may be limited to
pharmacological preconditioning
against excitotoxic injury, ischemia and/
or hypoxia.
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: May 2, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2013–10858 Filed 5–7–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up
Exclusive Evaluation Option License
Agreement: Gene Therapy and CellBased Therapy for Cardiac
Arrhythmias
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of a Start-Up
Exclusive Evaluation Option License
Agreement to Pace Biologics, LLC, a
company having a place of business in
Elkridge, Maryland, to practice the
inventions embodied in U.S. Provisional
Patent Application No. 61/180,491, filed
May 22, 2009 (HHS Ref. No. E–134–
2009/0–US–01), PCT Patent Application
No. PCT/US2010/035823, filed May 21,
2010 (HHS Ref. No. E–134–2009/0–
PCT–02), and U.S. Patent Application
No. 13/322,066, filed November 22,
2011 (HHS Ref. No. E–134–2009/0–US–
03), all entitled ‘‘Engineered Biological
Pacemakers.’’ The patent rights in these
inventions have been assigned to the
Government of the United States of
America. The territory of the
prospective Start-Up Exclusive
Evaluation Option License Agreement
may be worldwide, and the field of use
may be limited to ‘‘Gene therapy and
cell-based therapy for cardiac
arrhythmias in humans.’’
Upon the expiration or termination of
the Start-up Exclusive Evaluation
Option License Agreement, Pace
Biologics will have the exclusive right
to execute a Start-Up Exclusive Patent
SUMMARY:
E:\FR\FM\08MYN1.SGM
08MYN1
Agencies
[Federal Register Volume 78, Number 89 (Wednesday, May 8, 2013)]
[Notices]
[Pages 26793-26794]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-10854]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Aging Special Emphasis
Panel; Asthma in Older Adults.
Date: May 29, 2013.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute on Aging, Gateway Building, Suite
2C212, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Jeanette Johnson, Ph.D., Scientific Review
Branch, National Institute
[[Page 26794]]
on Aging, Gateway Building, 7201 Wisconsin Avenue, Suite 2C212,
Bethesda, MD 20892, 301-402-7705, JOHNSONJ9@NIA.NIH.GOV.
Name of Committee: National Institute on Aging Special Emphasis
Panel; Mild Cognitive Impairment.
Date: June 5, 2013.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute on Aging, Gateway Building, Suite
2C212, 7201 Wisconsin Avenue Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: William Cruce, Ph.D., Scientific Review Branch,
National Institute on Aging, Gateway Building, 7201 Wisconsin
Avenue, Suite 2C212, Bethesda, MD 20892, 301-402-7704,
crucew@nia.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging
Research, National Institutes of Health, HHS)
Dated: May 1, 2013.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-10854 Filed 5-7-13; 8:45 am]
BILLING CODE 4140-01-P